ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0374

Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study

Fabian Proft1, Julia Schally2, Henning Christian Brandt3, Jan Brandt-Jrgens4, Gerd Burmester1, Hildrun Haibel5, Henriette Käding2, Kirsten Karberg6, Susanne Lüders7, Burkhard Muche2, Mikhail Protopopov1, Judith Rademacher1, Valeria Rios Rodriguez1, Murat Torgutalp1, Maryna Verba8, Silke Zinke9 and Denis Poddubnyy10, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 3Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, 4Rheumatologische Schwerpunktpraxis, Berlin, Germany, 5Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 6Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, 7Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, 8Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 9Rheumapraxis Berlin, Berlin, Germany, 10Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

Meeting: ACR Convergence 2021

Keywords: , , ,

Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: According to international recommendations, the Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred score for assessing disease activity in axial spondyloarthritis (axSpA) [1]. However, routine determination of C-reactive protein (CRP) to calculate ASDAS values takes hours to days. This limits the use of ASDAS in clinical routine and clinical trials and hinders the implementation of treat-to-target approaches in axSpA. Whereas quick quantitative CRP (qCRP) tests allow CRP assessment within a few minutes. In a pilot project the performance of qCRP-based ASDAS assessment (ASDAS-qCRP) was already investigated in a single center study of 50 newly diagnosed, bDMARD-naïve axSpA patients with promising results [2]. Therefore, the objective of our study was to validate the ASDAS-qCRP in a prospective, multicenter study of axSpA patients in a typical axSpA cohort with an appropriate sample size.

Methods: The study was conducted in five centers in Germany. Consecutive adult (≥ 18 years) axSpA patients were included. In addition to a rheumatological assessment, including patient reported outcomes (PROs), routine CRP and erythrocyte sedimentation rate (ESR) were measured in the local labs. Additionally, a qCRP testing with the „QuikRead go instrument“ (Aidian Oy, Finland) was performed at the study center (measurement range 0.5 – 200 mg/l for hematocrit concentrations of 40 – 45%). Statistical analysis included descriptive statistics, cross tabulation and weighted Cohen´s kappa comparing disease activity categories, Bland-Altman plots and intraclass correlation coefficient (ICC) for ASDAS-CRP and ASDAS-qCRP.

Results: In this study 251 axSpA patients were included between January and September 2020 (mean age: 38.4 years; mean disease duration: 6.2 years, 159 patients (63.3%) were male, 211 (84.1%) HLA-B27 positive and 195 (77.7%) were classified as radiographic axSpA). 143 patients (57.0%) were treated with bDMARDs. CRP and qCRP showed mean values of 2.12 and 2.17 mg/l, respectively. With the ASDAS-qCRP, 242 patients (96.4%) were assigned to the same disease activity category as compared to the ASDAS based on the conventional lab CRP measurement (Table 1). Weighted Cohen´s kappa was 0.966 (95%CI: 0.943; 0.988). ICC for ASDAS-CRP- and ASDAS-qCRP-values was 0.997 (95%CI: 0.994; 0.999). The agreement of ASDAS-qCRP and ASDAS-CRP is shown in a Bland-Altman plot (Figure 1).

Conclusion: The ASDAS-qCRP and ASDAS-CRP showed an almost perfect agreement on the assignment to disease activity categories (96%) with the important advantage of time. With ASDAS-qCRP, rheumatologists could base their clinical decision-making on a disease activity measurement by using a composite score immediately. ASDAS-qCRP, therefore, can be integrated in clinical routine and clinical trials in the future and may facilitate implementation of the treat-to-target concept in axial SpA.

References:
1. Smolen JS, et al. Ann Rheum Dis. 2018 Jan; 77(1):3-17.
2. Proft F, et al. Joint Bone Spine. 2019 Jul 29.

Acknowledgements: The authors would like to deeply thank Braun T, Doerwald C, Deter N, Höppner C, Lackinger J, Lorenz C, Lunkwitz K, Mandt B, Sron S and Zernicke J for their practical support and coordinating the study.

Table 1: Disease activity categories by ASDAS-qCRP vs. ASDASCRP

Figure 1: Bland-Altman plot for ASDAS-qCRP and ASDAS-CRP

Disclosures: F. Proft, Novartis, 6; J. Schally, None; H. Brandt, None; J. Brandt-Jrgens, Abbvie, 2, 6, Pfizer, 2, 6, Roche, 2, 6, Sanofi-Aventis, 2, 6, Novartis, 2, 6, Eli Lilly, 2, 6, MSD, 2, 6, UCB, 2, 6, BMS, 2, 6, Janssen, 2, 6, Medac, 2, 6; G. Burmester, AbbVie, 2, 5, 6, Eli Lilly, 2, 5, 6, MSD, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, Sanofi, 2, 5, 6, UCB, 2, 5, 6, Galapagos, BV, 2, 6, Gilead Sciences, Inc., 2, 6; H. Haibel, Boehringer, 2, Janssen, 2, 6, MSD, 2, 6, Pfizer, 6, Novartis, 2, Roche, 2, 6, AbbVie, 6; H. Käding, None; K. Karberg, None; S. Lüders, None; B. Muche, None; M. Protopopov, Novartis, 1, 5, 6; J. Rademacher, None; V. Rios Rodriguez, None; M. Torgutalp, None; M. Verba, None; S. Zinke, None; D. Poddubnyy, AbbVie, 2, 5, 6, Eli Lilly and Company, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 6, BMS, 2, 6, Roche, 2, 6.

To cite this abstract in AMA style:

Proft F, Schally J, Brandt H, Brandt-Jrgens J, Burmester G, Haibel H, Käding H, Karberg K, Lüders S, Muche B, Protopopov M, Rademacher J, Rios Rodriguez V, Torgutalp M, Verba M, Zinke S, Poddubnyy D. Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/validation-of-the-ankylosing-spondylitis-disease-activity-score-with-a-quick-quantitative-creactiveprotein-assay-asdas-qcrp-in-patients-with-axial-spondyloarthritis-axspa-aprospective-national/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-ankylosing-spondylitis-disease-activity-score-with-a-quick-quantitative-creactiveprotein-assay-asdas-qcrp-in-patients-with-axial-spondyloarthritis-axspa-aprospective-national/